UXI Stock Overview
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cyclacel Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.26 |
| 52 Week High | US$10.20 |
| 52 Week Low | US$2.53 |
| Beta | 0.56 |
| 1 Month Change | 0% |
| 3 Month Change | 26.09% |
| 1 Year Change | -58.56% |
| 3 Year Change | -96.78% |
| 5 Year Change | -98.74% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| UXI | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | 1.1% |
| 1Y | -58.6% | -23.5% | 1.9% |
Return vs Industry: UXI underperformed the German Biotechs industry which returned 23.6% over the past year.
Return vs Market: UXI underperformed the German Market which returned 6.7% over the past year.
Price Volatility
| UXI volatility | |
|---|---|
| UXI Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: UXI has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine UXI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Spiro Rombotis | www.cyclacel.com |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias.
Cyclacel Pharmaceuticals, Inc. Fundamentals Summary
| UXI fundamental statistics | |
|---|---|
| Market cap | €2.94m |
| Earnings (TTM) | -€22.87m |
| Revenue (TTM) | €357.30k |
8.2x
P/S Ratio-0.1x
P/E RatioIs UXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UXI income statement (TTM) | |
|---|---|
| Revenue | US$389.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$389.00k |
| Other Expenses | US$25.29m |
| Earnings | -US$24.90m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Mar 19, 2024
| Earnings per share (EPS) | -18.89 |
| Gross Margin | 100.00% |
| Net Profit Margin | -6,402.06% |
| Debt/Equity Ratio | 0% |
How did UXI perform over the long term?
See historical performance and comparison